drugset / Trial / NCT00039234

Interleukin-2 With or Without Histamine Dihydrochloride in Treating Patients With Stage IV Melanoma Metastatic to the Liver

NCT00039234

RandomizedTreatment

Summary

RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill tumor cells. Histamine dihydrochloride may help interleukin-2 kill more tumor cells by making tumor cells more sensitive to the drug. It is not yet known if interleukin-2 is more effective with or without histamine dihydrochloride in treating stage IV melanoma that is metastatic to the liver. PURPOSE: Randomized phase III trial to compare the effectiveness of interleukin-2 with or without histamine dihydrochloride in treating patients who have stage IV melanoma that is metastatic to the liver.

Timeline

Start
2002-09
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Histamine Small molecule Subcutaneous
Subject aldesleukin Protein / enzyme biologic Subcutaneous